ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Price, Quote, News and Overview
NASDAQ:RARE - Nasdaq - US90400D1081 - Common Stock - Currency: USD
RARE Quote, Performance and Key Statistics
42.59
-1.89 (-4.25%)
The current stock price of RARE is 42.59 USD. In the past month the price decreased by -5.04%. In the past year, price decreased by -13.92%.
RARE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About RARE
Company Profile
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. The company is headquartered in Novato, California and currently employs 1,276 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
Company Info
ULTRAGENYX PHARMACEUTICAL IN
60 Leveroni Ct
Novato CALIFORNIA 94949 US
CEO: Emil D. Kakkis
Employees: 1276
Company Website: https://www.ultragenyx.com/
Investor Relations: https://ir.ultragenyx.com/
Phone: 14154838800
ULTRAGENYX PHARMACEUTICAL IN / RARE FAQ
What is the stock price of ULTRAGENYX PHARMACEUTICAL IN today?
The current stock price of RARE is 42.59 USD. The price decreased by -4.25% in the last trading session.
What is the ticker symbol for ULTRAGENYX PHARMACEUTICAL IN stock?
The exchange symbol of ULTRAGENYX PHARMACEUTICAL IN is RARE and it is listed on the Nasdaq exchange.
On which exchange is RARE stock listed?
RARE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ULTRAGENYX PHARMACEUTICAL IN stock?
26 analysts have analysed RARE and the average price target is 96.31 USD. This implies a price increase of 126.13% is expected in the next year compared to the current price of 42.59. Check the ULTRAGENYX PHARMACEUTICAL IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ULTRAGENYX PHARMACEUTICAL IN worth?
ULTRAGENYX PHARMACEUTICAL IN (RARE) has a market capitalization of 3.93B USD. This makes RARE a Mid Cap stock.
How many employees does ULTRAGENYX PHARMACEUTICAL IN have?
ULTRAGENYX PHARMACEUTICAL IN (RARE) currently has 1276 employees.
What are the support and resistance levels for ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?
ULTRAGENYX PHARMACEUTICAL IN (RARE) has a support level at 42.47 and a resistance level at 42.61. Check the full technical report for a detailed analysis of RARE support and resistance levels.
Is ULTRAGENYX PHARMACEUTICAL IN (RARE) expected to grow?
The Revenue of ULTRAGENYX PHARMACEUTICAL IN (RARE) is expected to grow by 19.14% in the next year. Check the estimates tab for more information on the RARE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RARE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RARE, evaluating the profitability, health, valuation and growth aspects
- ULTRAGENYX PHARMACEUTICAL IN (RARE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ULTRAGENYX PHARMACEUTICAL IN (RARE) Sales and EPS estimates to see what analysts future expectations are.
- ULTRAGENYX PHARMACEUTICAL IN (RARE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ULTRAGENYX PHARMACEUTICAL IN (RARE) Insider and Institutional Ownership to learn about the owners and their transactions.
- ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Chart to make your own analysis
- ULTRAGENYX PHARMACEUTICAL IN (RARE) Latest news and press-releases to stay up to date.
Does ULTRAGENYX PHARMACEUTICAL IN (RARE) stock pay dividends?
RARE does not pay a dividend.
When does ULTRAGENYX PHARMACEUTICAL IN (RARE) report earnings?
ULTRAGENYX PHARMACEUTICAL IN (RARE) will report earnings on 2025-04-30, after the market close.
What is the Price/Earnings (PE) ratio of ULTRAGENYX PHARMACEUTICAL IN (RARE)?
ULTRAGENYX PHARMACEUTICAL IN (RARE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.34).
What is the Short Interest ratio of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?
The outstanding short interest for ULTRAGENYX PHARMACEUTICAL IN (RARE) is 4.73% of its float. Check the ownership tab for more information on the RARE short interest.
RARE Technical Analysis
RARE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RARE. RARE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RARE Financial Highlights
Over the last trailing twelve months RARE reported a non-GAAP Earnings per Share(EPS) of -6.34. The EPS increased by 23.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.34% | ||
| ROE | -161.17% | ||
| Debt/Equity | 0 |
RARE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to RARE. The Buy consensus is the average rating of analysts ratings from 26 analysts.
For the next year, analysts expect an EPS growth of 15.05% and a revenue growth 19.14% for RARE